The cardiovascular and renal benefits of GLP-1 drugs are real and now well documented in outcome trials, but the receptor biology behind them is more indirect than it first appears
Incretin-based therapies and diabetic retinopathy: real-world evidence in Older U.S
These effects contribute to weight loss that varies by agent and dosetypically ranging from 5-8% with liraglutide 3 mg (Saxenda), up to 15% with semaglutide 2.4 mg (Wegovy), and potentially up to 20% with higher doses of tirzepatide (Zepbound)
The trade-off is a higher total cost due to the mandatory membership fee on top of medication
The Kisspeptin (Kiss1)-expressing neurons located in the ARC are responsible for gonadotropin-releasing hormone (GnRH)/luteinizing hormone (LH) release (Li et al., 2009
As a glucagon-like peptide-1 (GLP-1) receptor agonist, GLP-1 Treatments, Semaglutide or Tirzepatide mimics the action of the body's natural GLP-1 hormone